IRIDEX Corporation Common Stock (IRIX)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary when a company has a useful product but cannot earn a profit. IRIDEX sells ophthalmic laser systems and consumables for glaucoma and retinal disease, a narrow technical market. In fiscal Q2 2026, the quarter ended 2026-07-04, revenue was $12.6 million and net income was -$1.3 million; that revenue was below the $13.6 million in fiscal Q2 2025, the quarter ended 2025-06-28. For fiscal 2025, ended 2026-01-03, revenue was $52.7 million and net income was -$4.4 million, an improvement from -$8.9 million in fiscal 2024 and -$9.6 million in fiscal 2023, but still a loss. The supplied growth figures are negative: revenue growth of -7.41% and profit growth of -27.36%. At the $0.85 close on 2026-10-13 and a $14.9 million market cap, FairStock calculations show P/E -4.25, P/B N/A, ROE -73.15%, ROCE -5.90%, FCF yield -13.4%, D/E 1.10, and Altman Z-score -3.65. Piotroski is 5/9, and there is no Peter Lynch category because losses persist each of the last four years. FairStock Score is 34/100. The crux is cash: trailing free cash flow is -$2.0 million. A small niche and low beta do not create a moat if the business cannot generate cash. Without a clear path to durable profits, the low price may reflect a weak business rather than a bargain.

In plain English: IRIDEX makes laser systems and instruments that eye doctors use for glaucoma and retinal diseases. The business has been losing money for years, sales slipped in the latest comparable quarter, and it burns cash, so the underlying results look weak. At $0.85 a share, the price is very small, but versus those weak numbers it does not look clearly cheap; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-07-04) · fiscal Q1 2026 10-Q (period ended 2026-04-04) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2026-01-03) · FY2024 10-K (period ended 2024-12-28) · FY2023 10-K (period ended 2023-12-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer